13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001306923
Total reported value
$723.7M
$723.7M
44 檔
35.9%
According to the latest 13F quarterly dataset, Palo Alto Investors LP managed an equity portfolio of $723.7M at the end of Q3 2025, spanning 44 distinct U.S. exchange-listed positions.
In Q3 2025, Palo Alto Investors LP adopted a defensive or profit-taking posture, trimming 19 positions and completely liquidating 8 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 13.11% | -4.29% | -43.15% | |
| 2 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 9.80% | +0.76% | +112.22% | |
| 3 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 9.74% | +0.23% | -3.77% | |
| 4 | AM6 | Amicus Therapeutics Inc | Stock-Other | 7.83% | -2.46% | EXIT | |
| 5 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 7.56% | -0.52% | -10.29% | |
| 6 | BIIB | Biogen Inc | Stock-Healthcare | 4.81% | +0.24% | -9.77% | |
| 7 | UTHR | United Therapeutics CORP | Stock-Healthcare | 4.51% | -1.01% | -39.06% | |
| 8 | ANAB | Anaptysbio Inc | Stock-Other | 3.82% | +0.22% | -17.14% | |
| 9 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 3.06% | -0.37% | +122.15% | |
| 10 | NVCR | NovoCure Limited | Stock-Healthcare | 3.00% | +0.55% | +30.52% | |
| 11 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.96% | +0.48% | +376.52% | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 2.74% | +0.28% | +53.96% | |
| 13 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.73% | — | -57.21% | |
| 14 | GOSS | Gossamer Bio Inc | Stock-Other | 2.66% | — | -4.79% | |
| 15 | PRTA | Prothena Corporation plc | Stock-Other | 2.39% | -0.25% | +3.87% | |
| 16 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.06% | +0.84% | +658.01% | |
| 17 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.97% | -0.01% | -1.22% | |
| 18 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.86% | -0.48% | +47.38% | |
| 19 | EHTH | Ehealth Inc | Stock-Other | 1.23% | +0.02% | -2.11% | |
| 20 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.10% | -0.69% | EXIT | |
| 21 | ALGN | Align Technology Inc | Stock-Healthcare | 1.06% | -0.36% | +21.08% | |
| 22 | ALKS | Alkermes plc | Stock-Healthcare | 1.02% | +0.45% | -16.78% | |
| 23 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.89% | — | -7.62% | |
| 24 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.88% | +1.05% | — | |
| 25 | CDNA | Caredx Inc | Stock-Other | 0.85% | +0.68% | — | |
| 26 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.75% | +0.36% | — | |
| 27 | NUVB | Nuvation Bio Inc | Stock-Other | 0.70% | -0.07% | +32.08% | |
| 28 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.55% | +0.25% | +12.72% | |
| 29 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.49% | +0.01% | -7.62% | |
| 30 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.49% | +0.27% | — | |
| 31 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.48% | +0.01% | -14.78% | |
| 32 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.47% | +0.06% | +35.87% | |
| 33 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.46% | -0.04% | -16.24% | |
| 34 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.43% | +0.13% | — | |
| 35 | BNTX | Biontech Se-adr | Stock-Other | 0.36% | -0.02% | -22.19% | |
| 36 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.32% | -0.02% | -11.19% | |
| 37 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.22% | +0.01% | — | |
| 38 | HUM | Humana Inc | Stock-Healthcare | 0.19% | +0.11% | — | |
| 39 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.15% | -0.01% | — | |
| 40 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.11% | +0.02% | — | |
| 41 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.09% | +0.05% | — | |
| 42 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.07% | — | — | |
| 43 | ✓ | Akari Therapeutics PLC | Stock-Other | 0.03% | — | — | |
| 44 | GBIOGBX | Generation Bio Co | Stock-Other | 0.02% | — | -90.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PTCT | Ptc Therapeutics Inc | +5.9% | +112.22% | Add |
| 2 | DYN | Dyne Therapeutics Inc | +2.3% | +376.52% | Add |
| 3 | GOSS | Gossamer Bio Inc | +1.4% | -4.79% | Trim |
| 4 | ACAD | Acadia Pharmaceuticals Inc | +1.3% | -3.77% | Trim |
| 5 | IOVA | Iovance Biotherapeutics Inc | +1% | +122.15% | Add |
| 6 | SNDX | Syndax Pharmaceuticals Inc | +0.8% | +47.38% | Add |
| 7 | NUVB | Nuvation Bio Inc | +0.4% | +32.08% | Add |
| 8 | AGIO | Agios Pharmaceuticals Inc | +0.4% | -1.22% | Trim |
| 9 | TSHA | Taysha Gene Therapies Inc | +0.4% | — | Trim |
| 10 | MIRM | Mirum Pharmaceuticals Inc | +0.3% | — | Unchanged |
| 11 | ACRS | Aclaris Therapeutics Inc | +0.3% | +12.72% | Add |
| 12 | STOK | Stoke Therapeutics Inc | +0.3% | -16.24% | Trim |
| 13 | PYXS | Pyxis Oncology Inc | +0.2% | — | Unchanged |
| 14 | ANAB | Anaptysbio Inc | +0.2% | -17.14% | Trim |
| 15 | NBIX | Neurocrine Biosciences Inc | +0.2% | +35.87% | Add |
| 16 | TVTX | Travere Therapeutics Inc | +0.1% | — | Unchanged |
| 17 | URGN | UroGen Pharma Ltd. | 0% | — | Unchanged |
| 18 | ABEO | Abeona Therapeutics Inc | 0% | — | Unchanged |
| 19 | GBIOGBX | Generation Bio Co | 0% | -90.00% | Trim |
| 20 | ✓ | Akari Therapeutics PLC | — | — | Unchanged |
| 21 | HUM | Humana Inc | 0% | — | Unchanged |
| 22 | ALDX | Aldeyra Therapeutics Inc | 0% | — | Unchanged |
| 23 | EW | Edwards Lifesciences CORP | -0.1% | -14.78% | Trim |
| 24 | BCYC | Bicycle Therapeutics Plc-adr | -0.1% | -11.19% | Trim |
| 25 | BNTX | Biontech Se-adr | -0.1% | -22.19% | Trim |
| 26 | ALGN | Align Technology Inc | -0.1% | +21.08% | Add |
| 27 | ALKS | Alkermes plc | -0.4% | -16.78% | Trim |
| 28 | NVCR | NovoCure Limited | -0.4% | +30.52% | Add |
| 29 | BIIB | Biogen Inc | -0.5% | -9.77% | Trim |
| 30 | EHTH | Ehealth Inc | -0.9% | -2.11% | Trim |
| 31 | INSM | Insmed Inc | -1.2% | -43.15% | Trim |
| 32 | PRTA | Prothena Corporation plc | -1.5% | +3.87% | Trim |
| 33 | ALNY | Alnylam Pharmaceuticals Inc | -1.6% | -57.21% | Trim |
| 34 | UTHR | United Therapeutics CORP | -1.7% | -39.06% | Trim |
| 35 | AM6 | Amicus Therapeutics Inc | -3.6% | -4.33% | Trim |
| 36 | BMRN | Biomarin Pharmaceutical Inc | -5.8% | -10.29% | Trim |
| 37 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 38 | SRPT | Sarepta Therapeutics Inc | — | EXIT | Sold out |
| 39 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 40 | STAA | Staar Surgical Co | — | EXIT | Sold out |
| 41 | DNLI | Denali Therapeutics Inc | — | NEW | New buy |
| 42 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 43 | CDNA | Caredx Inc | — | NEW | New buy |
| 44 | ✓ | Acelyrin Inc | — | EXIT | Sold out |
| 45 | CRSP | CRISPR Therapeutics AG | — | NEW | New buy |
| 46 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 47 | KPTIEUR | Karyopharm Therapeutics Inc | — | EXIT | Sold out |
| 48 | ORKA | Oruka Therapeutics Inc | — | NEW | New buy |
| 49 | VYNE | Vyne Therapeutics Inc | — | EXIT | Sold out |
| 50 | ✓ | Proqr Therapeutics N.v. | — | NEW | New buy |
According to official SEC Form 13F filings, Palo Alto Investors LP reported a total U.S. public equity portfolio value of $723.7M across 44 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, PTCT, ACAD) accounted for 35.9% of total reported equity market value during Q3 2025.
Top New Position Initiated
IRON
市值: $14.8M
Top Position Liquidated / Trimmed
SRPT
前期市值: $13.4M
During Q3 2025, Palo Alto Investors LP's top holdings by market value included INSM (13.1%)、PTCT (9.8%)、ACAD (9.7%). The largest single position, INSM, represented 13.1% of total portfolio value.
In Q3 2025, Palo Alto Investors LP made 44 total portfolio adjustments, initiating 8 new buys, adding to 9 positions, trimming 19 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.